Market capitalization | KRW36.45t |
Enterprise Value | KRW37.60t |
P/E (TTM) P/E ratio | 195.10 |
EV/FCF (TTM) EV/FCF | 66.23 |
EV/Sales (TTM) EV/Sales | 13.07 |
P/S ratio (TTM) P/S ratio | 12.67 |
P/B ratio (TTM) P/B ratio | 2.16 |
Dividend yield | 0.28% |
Last dividend (FY22) | KRW500.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
20 Analysts have issued a Celltrion forecast:
20 Analysts have issued a Celltrion forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,876,253 2,876,253 |
25%
25%
|
|
Gross Profit | 1,110,456 1,110,456 |
4%
4%
|
|
EBITDA | 726,316 726,316 |
24%
24%
|
EBIT (Operating Income) EBIT | 314,009 314,009 |
57%
57%
|
Net Profit | 187,097 187,097 |
69%
69%
|
In millions KRW.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.
Head office | South Korea |
CEO | Wu-Sung Ki |
Employees | 2,529 |
Founded | 1991 |
Website | www.celltrion.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.